Salmeterol is a selective β 2 -agonist indicated for reversible airways obstruction in patients with asthma and chronic obstructive pulmonary disease (COPD). In asthma (including nocturnal asthma and exercise induced symptoms) it is indicated for those treated with inhaled corticosteroids who require a long-acting beta agonist in accordance with current treatment guidelines. Serevent Accuhaler is not a replacement for inhaled or oral corticosteroids which should be continued at the same dose, and not stopped or reduced, when treatment with Serevent Accuhaler is initiated.
Asthma Serevent is indicated for the regular symptomatic add-on treatment of reversible airways obstruction in patients with asthma, including those with nocturnal asthma, who are inadequately controlled on inhaled corticosteroids in accordance with current treatment guidelines. Serevent is also indicated in the prevention of exercise-induced asthma. Chronic Obstructive Pulmonary Disease (COPD) Serevent is indicated in the treatment of patients with COPD.
GlaxoSmithKline has announced results from the safety study AUSTRI (SAS115359) comparing Advair Diskus, a combination of the LABA salmeterol and...
The FDA has approved the first generic of Advair Diskus (fluticasone propionate and salmeterol inhalation powder) for the twice-daily treatment...
GlaxoSmithKline announced publication of results from the safety study, AUSTRI (SAS115359) in the New England Journal of Medicine (NEJM). The...